Premium
CD markers variations in chronic lymphocytic leukemia: New insights into prognosis
Author(s) -
Vosoughi Tina,
Bagheri Marziye,
Hosseinzadeh Mehran,
Ehsanpour Ali,
Davari Nader,
Saki Najmaldin
Publication year - 2019
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.28724
Subject(s) - chronic lymphocytic leukemia , pathogenesis , organomegaly , immunology , disease , bone marrow , leukemia , medicine , hematology , haematopoiesis , cancer research , biology , pathology , stem cell , genetics
Chronic lymphocytic leukemia (CLL) is one of the most commonly occurring adult leukemias that is associated with clonal accumulation of mature apoptosis‐resistant B‐cells in bone marrow, peripheral blood, and specific tissues. Different pathogenesis factors can contribute to the aggression of the clinical course in this disease. Cytogenetic abnormalities and surface biomarkers of neoplastic CLL cells can be effective in the outcome of CLL, and the examination of changing CD markers expressions in the progression of CLL can be related to the prognosis of this disease. Changing expression levels of CD markers on lymphocytes and other cells in CLL patients can play a role in the aggressive clinical outcomes such as organomegaly, immunodeficiency, and advanced disease stages through their interaction with CLL microenvironment. Given the involvement of CD markers in the pathogenesis of CLL, it can be stated that recognizing the expression changes of CD markers in the cells involved in CLL can be a proper approach to evaluate prognosis among these patients.